ACME Laboratories (DHA:ACMELAB) EBIT: BDT4,986 Mil (TTM As of Mar. 2026)


DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
82 GF Score
Price BDT81.30
GF Value BDT124.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories EBIT?

ACME Laboratories DHA:ACMELAB +0.37% 82 EBIT is BDT4,986 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review.

ACME Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was BDT1,559 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT4,986 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ACME Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 was 8.95%. ACME Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ACME Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.99%.


ACME Laboratories  (DHA:ACMELAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ACME Laboratories's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=6272.368 * ( 1 - 19.86% )/( (55865.238 + 56412.107)/ 2 )
=5026.6757152/56138.6725
=8.95 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=60115.544 - 1241.963 - ( 3008.343 - max(0, 22998.137 - 26971.644+3008.343))
=55865.238

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=59535.015 - 532.683 - ( 2590.225 - max(0, 21886.899 - 26221.882+2590.225))
=56412.107

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

ACME Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6236.384/( ( (33060.133 + max(18199.615, 0)) + (33181.303 + max(18376.384, 0)) )/ 2 )
=6236.384/( ( 51259.748 + 51557.687 )/ 2 )
=6236.384/51408.7175
=12.13 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3691.869 + 12373.289 + 7768.35) - (1241.963 + 0 + 4391.93)
=18199.615

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3702.081 + 12068.55 + 7836.21) - (532.683 + 0 + 4697.774)
=18376.384

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ACME Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=4985.91/38369.432
=12.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ACME Laboratories EBIT Related Terms


ACME Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories EBIT Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT
Get a 7-Day Free Trial Premium Member Only 3,752.38 3,665.49 3,990.33 4,332.32 5,501.04

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,667.16 1,719.96 1,689.94 1,736.88 1,559.10

DHA:ACMELAB vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACME Laboratories EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ACME Laboratories's EV-to-EBIT falls into.


DHA:ACMELAB
82GF Score
ACME Laboratories Ltd DHA:ACMELAB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT4,986 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of BDT4,986 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a EBIT of BDT4,986 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ACME Laboratories.
Is ACME Laboratories' EBIT too high?
ACME Laboratories' current EBIT is BDT4,986 Mil. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' EBIT compare to ZTS and UTHR?
ACME Laboratories' EBIT of BDT4,986 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ACME Laboratories. ACME Laboratories's current EBIT is BDT4,986 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current EBIT is BDT4,986 Mil. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current EBIT is BDT4,986 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • EBIT: BDT4,986 Mil
  • GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score

Get the complete analysis for DHA:ACMELAB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT81.30
Price
BDT124.74
GF Value